CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Glutamin +1 moredrug
Likely dose
Glutamin 0.3gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03113240
NCT03113240Phase 3Completed
CompareCT.gov

Effects of Enteral Glutamine on Intestinal Permeability in Hospitalized Patients With Enteral Feeding in Intensive Care Unit

Shahid Beheshti University·interventional·Posted Apr 13, 2017·Updated Apr 10, 2018

In Brief

A Phase 3 clinical trial evaluating Glutamin and Maltodextrin for Critical Illness and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Glutamine-induced recovery in intestinal barrier function by reducing bacterial translocation was demonstrated in previous studies. In this trial, intensive care unit patients with enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 10 days and the effects of the intervention on intestinal permeability will be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Illness, Enteral Nutrition, Intestinal Permeability
CountriesIran
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 13, 2017
Enrollment StartApr 1, 2017
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.2 years ago

Interventions

Glutamindrug

Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.

Maltodextrinother

Maltodextrin mixed with water given via NG tube q 4 hours.